Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect of CKD-378 in Healthy Volunteers
NCT06709807Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-time Curve from time 0 to the last measurable concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Started Nov 2024; status: completed.
02
Drugs
empagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06709807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06709807.